Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAIRO3: Maintenance capecitabine + bevacizumab versus observation after induction CAPOX + bevacizumab in advanced colorectal cancer
2006-006657-27Phase 3Active
- Sponsor
- Dutch Colorectal Cancer Group
- Start
- Dec 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in colorectal cancer (CRC) comparing Observation after induction with Maintenance capecitabine + bevacizumab (2 arms). Primary endpoint: Progression-free survival (PFS2). Started Dec 2006; status: active.
02
Drugs
capecitabinebevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2006-006657-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006657-27.